{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:41:48Z","timestamp":1792431708901,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"am","delay-in-days":305,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"NIDA CTN","doi-asserted-by":"publisher","award":["UG1DA013035"],"award-info":[{"award-number":["UG1DA013035"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"NIDA CTN","doi-asserted-by":"publisher","award":["UG1DA015831"],"award-info":[{"award-number":["UG1DA015831"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.cct.2024.107543","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T21:43:47Z","timestamp":1713822227000},"page":"107543","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Discontinuation of medication treatment for opioid use disorder after a successful course: The discontinuation phase of the CTN-0100 (RDD) trial"],"prefix":"10.1016","volume":"142","author":[{"given":"Matisyahu","family":"Shulman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Provost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn","family":"Ohrtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Novo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Meyers-Ohki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Van Veldhuisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Oden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Otterstatter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genie L.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Rotrosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward V.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger D.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.cct.2024.107543_bb0015","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1037\/a0013637","article-title":"Addiction to prescription opioids: Characteristics of the emerging epidemic and treatment with buprenorphine","volume":"16","author":"Mendelson","year":"2008","journal-title":"Exp. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.cct.2024.107543_bb0020","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cct.2010.01.003","article-title":"A multi-site, two-phase, prescription opioid addiction treatment study (POATS): rationale, design, and methodology","volume":"31","author":"Weiss","year":"2010","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.cct.2024.107543_bb0025","series-title":"Medicine NA of S Engineering, and, Division H and M, Policy B on HS, Disorder C on MAT for OU. Medications for Opioid Use Disorder Save Lives","year":"2019"},{"key":"10.1016\/j.cct.2024.107543_bb0065","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.drugalcdep.2017.03.013","article-title":"Effectiveness of treatment for opioid use disorder: a national, five-year, prospective, observational study in England","volume":"176","author":"Eastwood","year":"2017","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"10.1016\/j.cct.2024.107543_bb0075","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/add.13238","article-title":"Long-term outcomes after randomization to buprenorphine\/naloxone versus methadone in a multi-site trial","volume":"111","author":"Hser","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.cct.2024.107543_bb0080","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.02.030","article-title":"Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study","volume":"150","author":"Weiss","year":"2015","journal-title":"Drug Alcohol Depend."},{"issue":"12","key":"10.1016\/j.cct.2024.107543_bb0040","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1111\/add.15959","article-title":"Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study","volume":"117","author":"Burns","year":"2022","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.cct.2024.107543_bb0045","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jsat.2006.11.009","article-title":"Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients","volume":"33","author":"Maremmani","year":"2007","journal-title":"J. Subst. Abus. Treat."},{"issue":"2","key":"10.1016\/j.cct.2024.107543_bb0070","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1176\/appi.ajp.2019.19060612","article-title":"Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder","volume":"177","author":"Williams","year":"2020","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.cct.2024.107543_bb0050","doi-asserted-by":"crossref","DOI":"10.1097\/ADM.0000000000000584","article-title":"Comparing reasons for starting and stopping methadone, buprenorphine, and naltrexone treatment among a sample of white individuals with opioid use disorder","volume":"14","author":"Randall-Kosich","year":"2020","journal-title":"J. Addict. Med."},{"issue":"4","key":"10.1016\/j.cct.2024.107543_bb0055","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/ajad.12884","article-title":"Worries about discontinuing buprenorphine treatment: scale development and clinical correlates","volume":"28","author":"Stein","year":"2019","journal-title":"Am. J. Addict."},{"issue":"2","key":"10.1016\/j.cct.2024.107543_bb0060","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1176\/appi.ajp.2019.19121245","article-title":"Discontinuing buprenorphine treatment of opioid use disorder: what do we (not) know?","volume":"177","author":"Connery","year":"2020","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.cct.2024.107543_bb0110","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1186\/s13063-016-1726-1","article-title":"The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial","volume":"17","author":"Gustafson","year":"2016","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.cct.2024.107543_bb0085","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1037\/0003-066X.55.1.68","article-title":"Self-determination theory and the facilitation of intrinsic motivation, social development, and well-being","volume":"55","author":"Ryan","year":"2000","journal-title":"Am. Psychol."},{"issue":"7","key":"10.1016\/j.cct.2024.107543_bb0120","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1176\/appi.ajp.2008.07111835","article-title":"Computer-assisted delivery of cognitive-behavioral therapy for addiction: a randomized trial of CBT4CBT","volume":"165","author":"Carroll","year":"2008","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.cct.2024.107543_bb0125","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1176\/appi.ajp.2013.13070987","article-title":"Computer-assisted delivery of cognitive-behavioral therapy: efficacy and durability of CBT4CBT among cocaine-dependent individuals maintained on methadone","volume":"171","author":"Carroll","year":"2014","journal-title":"Am. J. Psychiatry"},{"issue":"10","key":"10.1016\/j.cct.2024.107543_bb0090","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s11606-012-2077-6","article-title":"Shared decision making: a model for clinical practice","volume":"27","author":"Elwyn","year":"2012","journal-title":"J. Gen. Intern. Med."},{"issue":"17","key":"10.1016\/j.cct.2024.107543_bb0095","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","article-title":"Combined pharmacotherapies and behavioral interventions for alcohol dependencethe COMBINE study: a randomized controlled trial","volume":"295","author":"Anton","year":"2006","journal-title":"JAMA"},{"issue":"9776","key":"10.1016\/j.cct.2024.107543_bb0100","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial","volume":"377","author":"Krupitsky","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2024.107543_bb0105","doi-asserted-by":"crossref","unstructured":"Counseling Plus Buprenorphine\u2013Naloxone Maintenance Therapy for Opioid Dependence | NEJM. Accessed October 11, 2023. https:\/\/doi.org\/10.1056\/NEJMoa055255.","DOI":"10.1056\/NEJMoa055255"},{"issue":"4","key":"10.1016\/j.cct.2024.107543_bb0165","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1360-0443.1988.tb00485.x","article-title":"Reliability of a timeline method: assessing normal drinkers\u2019 reports of recent drinking and a comparative evaluation across several populations","volume":"83","author":"Sobell","year":"1988","journal-title":"Br. J. Addict."},{"key":"10.1016\/j.cct.2024.107543_bb0170","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/SAR.S239507","article-title":"An updated version of the treatment effectiveness assessment (TEA) [letter]","volume":"11","author":"Ling","year":"2020","journal-title":"Subst. Abus. Rehabil."},{"key":"10.1016\/j.cct.2024.107543_bb0175","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.drugalcdep.2014.10.002","article-title":"Assessing craving and its relationship to subsequent prescription opioid use among treatment-seeking prescription opioid dependent patients","volume":"145","author":"McHugh","year":"2014","journal-title":"Drug Alcohol Depend."},{"issue":"5","key":"10.1016\/j.cct.2024.107543_bb0180","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/QAI.0b013e31817efb6e","article-title":"Effectiveness of HIV\/STD sexual risk reduction groups for women in substance abuse treatment programs: results of NIDA clinical trials network trial","volume":"48","author":"Tross","year":"2008","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.cct.2024.107543_bb0185","doi-asserted-by":"crossref","unstructured":"Full Article: Men in Methadone Maintenance versus Psychosocial Outpatient Treatment: Differences in Sexual Risk Behaviors and Intervention Effectiveness from a Multisite HIV Prevention Intervention Trial. Accessed October 11, 2023. https:\/\/doi.org\/10.1080\/10550887.2010.489451.","DOI":"10.1080\/10550887.2010.489451"},{"issue":"1","key":"10.1016\/j.cct.2024.107543_bb0190","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1037\/a0028445","article-title":"The short inventory of problems \u2013 revised (SIP-R): psychometric properties within a large, diverse sample of substance use disorder treatment seekers","volume":"27","author":"Kiluk","year":"2013","journal-title":"Psychol. Addict. Behav."},{"key":"10.1016\/j.cct.2024.107543_bb0195","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.drugalcdep.2017.03.022","article-title":"Development and validation of a brief assessment of recovery capital (BARC-10) for alcohol and drug use disorder","volume":"177","author":"Vilsaint","year":"2017","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"10.1016\/j.cct.2024.107543_bb0200","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1037\/a0025094","article-title":"Domain-general and domain-specific strategies for the assessment of distress intolerance","volume":"25","author":"McHugh","year":"2011","journal-title":"Psychol. Addict. Behav."},{"issue":"3","key":"10.1016\/j.cct.2024.107543_bb0205","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.beth.2011.12.001","article-title":"Refining the measurement of distress intolerance","volume":"43","author":"McHugh","year":"2012","journal-title":"Behav. Ther."},{"issue":"7","key":"10.1016\/j.cct.2024.107543_bb0210","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jpain.2016.03.004","article-title":"Distress intolerance and prescription opioid misuse among patients with chronic pain","volume":"17","author":"McHugh","year":"2016","journal-title":"J. Pain"},{"issue":"2","key":"10.1016\/j.cct.2024.107543_bb0215","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/00223890802634290","article-title":"Development and validation of the short grit scale (grit\u2013S)","volume":"91","author":"Duckworth","year":"2009","journal-title":"J. Pers. Assess."},{"key":"10.1016\/j.cct.2024.107543_bb0220","series-title":"The Social Psychology of Health. The Claremont Symposium on Applied Social Psychology","first-page":"31","article-title":"Perceived stress in a probability sample of the United States","author":"Cohen","year":"1988"},{"issue":"4","key":"10.1016\/j.cct.2024.107543_bb0225","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2307\/2136404","article-title":"A global measure of perceived stress","volume":"24","author":"Cohen","year":"1983","journal-title":"J. Health Soc. Behav."},{"issue":"9","key":"10.1016\/j.cct.2024.107543_bb0240","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9","volume":"16","author":"Kroenke","year":"2001","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.cct.2024.107543_bb0245","first-page":"508","article-title":"HITS: a short domestic violence screening tool for use in a family practice setting","volume":"30","author":"Sherin","year":"1998","journal-title":"Fam. Med."},{"issue":"11","key":"10.1016\/j.cct.2024.107543_bb0250","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jclinepi.2010.04.011","article-title":"The patient-reported outcomes measurement information system (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005\u20132008","volume":"63","author":"Cella","year":"2010","journal-title":"J. Clin. Epidemiol."},{"issue":"7","key":"10.1016\/j.cct.2024.107543_bb0255","volume":"13","year":"2023","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.cct.2024.107543_bb0260","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/00005650-199907000-00006","article-title":"Accuracy of self-reported health services use and patterns of care among urban older adults","volume":"37","author":"Wallihan","year":"1999","journal-title":"Med. Care"},{"issue":"9","key":"10.1016\/j.cct.2024.107543_bb0265","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/0895-4356(96)00143-6","article-title":"Comparison of self-reported and medical record health care utilization measures","volume":"49","author":"Roberts","year":"1996","journal-title":"J. Clin. Epidemiol."},{"issue":"2","key":"10.1016\/j.cct.2024.107543_bb0270","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/oxfordjournals.aje.a115129","article-title":"Agreement between questionnaire data and medical records. The evidence for accuracy of recall","volume":"129","author":"Harlow","year":"1989","journal-title":"Am. J. Epidemiol."},{"issue":"6","key":"10.1016\/j.cct.2024.107543_bb0130","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/ADM.0000000000000789","article-title":"Discontinuing methadone and buprenorphine: a review and clinical challenges","volume":"15","author":"Zweben","year":"2021","journal-title":"J. Addict. Med."},{"issue":"5","key":"10.1016\/j.cct.2024.107543_bb0135","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1080\/09595230801956165","article-title":"How large must a treatment effect be before it matters to practitioners? An estimation method and demonstration","volume":"27","author":"Miller","year":"2008","journal-title":"Drug Alcohol Rev."},{"issue":"1\u20132","key":"10.1016\/j.cct.2024.107543_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2011.05.033","article-title":"The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review","volume":"119","author":"Dunn","year":"2011","journal-title":"Drug Alcohol Depend."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714424001265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714424001265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T20:59:22Z","timestamp":1757624362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714424001265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":43,"alternative-id":["S1551714424001265"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2024.107543","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discontinuation of medication treatment for opioid use disorder after a successful course: The discontinuation phase of the CTN-0100 (RDD) trial","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2024.107543","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107543"}}